Literature DB >> 26608461

Vesicle-associated microRNAs are released from blood cells on incubation of blood samples.

Verena Köberle1, Bianca Kakoschky1, Ahmed Atef Ibrahim1, Christian Schmithals1, Jan Peveling-Oberhag1, Stefan Zeuzem1, Bernd Kronenberger1, Oliver Waidmann1, Thomas Pleli1, Albrecht Piiper2.   

Abstract

MicroRNAs (miRNAs) circulating extracellularly in the blood are currently intensively studied as novel disease markers. However, the preanalytical factors influencing the levels of the extracellular miRNAs are still incompletely explored. In particular, it is unknown, whether the incubation of blood samples as occurring in clinical routine can lead to a release of miRNAs from blood cells and thus alter the extracellular miRNA levels before the preparation of serum or plasma from the blood cells. Using a set of marker miRNAs and quantitative RT-PCR, we found that the levels of extracellular miRNA-1, miRNA-16, and miRNA-21 were increased in EDTA and serum collection tubes incubated for 1-3 hours at room temperature and declined thereafter; the levels of the liver-specific miRNA-122 declined monophasically. These events occurred in the absence of significant hemolysis. When the blood was supplemented with Ribonuclease A inhibitor, the levels of miRNA-1, miRNA-16, and miRNA-21 increased substantially during the initial 3 hours of incubation and those of miRNA-122 remained unchanged, indicating that the release of blood cell-derived miRNAs occurred during the initial 3 hours of incubation of the blood tubes, but not at later time points. Separation of 5-hour preincubated blood into vesicle and nonvesicle fractions revealed a selective increase in the portion of vesicle-associated miRNAs. Together, these data indicate that the release of vesicle-associated miRNAs from blood cells can occur in blood samples within the time elapsing in normal clinical practice until their processing without significant hemolysis. This becomes particularly visible on the inhibition of miRNA degradation by Ribonuclease A inhibitor.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26608461     DOI: 10.1016/j.trsl.2015.10.010

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  4 in total

1.  MicroRNAs as Novel Biomarkers of Deployment Status and Exposure to Polychlorinated Dibenzo-p-Dioxins/Dibenzofurans.

Authors:  Collynn F Woeller; Thomas H Thatcher; Daniel Van Twisk; Stephen J Pollock; Amanda Croasdell; Philip K Hopke; Xiaoyan Xia; Juilee Thakar; Patricia J Sime; Timothy M Mallon; Mark J Utell; Richard P Phipps
Journal:  J Occup Environ Med       Date:  2016-08       Impact factor: 2.162

2.  Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer.

Authors:  Dennis Poel; Tineke E Buffart; Jolanda Oosterling-Jansen; Henk Mw Verheul; Jens Voortman
Journal:  Exp Mol Med       Date:  2018-03-09       Impact factor: 8.718

Review 3.  Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.

Authors:  Sophie L Mumford; Benjamin P Towler; Amy L Pashler; Onur Gilleard; Yella Martin; Sarah F Newbury
Journal:  Biomolecules       Date:  2018-04-26

4.  Comparison of miRNA quantitation by Nanostring in serum and plasma samples.

Authors:  Catherine Foye; Irene K Yan; Waseem David; Neha Shukla; Yacob Habboush; Lori Chase; Kristen Ryland; Vivek Kesari; Tushar Patel
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.